Related Experiment Video
Updated: Jan 3, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Long Non-Coding RNA CDKN2B-AS1 Facilitates Laryngeal Squamous Cell Cancer Through Regulating miR-497/CDK6 Pathway
Xiangyan Cui1, Tingting Yu1, Jing Shang1
1Department of Otolaryngology-Head and Neck Surgery, The First Hospital of Jilin University, Changchun 130021, People's Republic of China.
Background:
CDKN2B antisense RNA 1 (CDKN2B-AS1), a long noncoding RNA, was reported to play crucial roles in the progression of multiple cancers. However, the functional roles and regulatory mechanism of CDKN2B-AS1 in human laryngeal squamous cell cancer (LSCC) remain unclear. The goals of this study were to investigate biological roles and underlying mechanisms of CDKN2B-AS1 in LSCC.
Methods:
The expressions of CDKN2B-AS1, miR-497 and cyclin-dependent kinase 6 (CDK6) were detected in LSCC tissues and cell lines by real-time quantitative PCR (qRT-PCR). The effects of CDKN2B-AS1 on LSCC cell proliferation, apoptosis, migration and invasion were examined by corresponding experiments. Bioinformatics analysis and luciferase activity assay were applied to analyze the interaction between CDKN2B-AS1 and miR-497.
Results:
The expression of CDKN2B-AS1 was significantly higher in LSCC tissues than in adjacent normal tissues. Higher CDKN2B-AS1 was closely associated with lymph node metastasis and advanced clinical stage. Moreover, CDKN2B-AS1 knockdown by siRNA significantly inhibited the proliferation, induced cell apoptosis, and suppressed migration and invasion in LSCC cells. Mechanically, CDKN2B functions as an oncogenic lncRNA in LSCC via regulating miR-497/CDK6 axis.
Conclusion:
The observations in this study identify CDKN2B-AS1 an oncogenic role in the tumorigenesis of LSCC by regulating miR-497/CDK6 axis and indicate that it may serve as a potential target for LSCC treatment.
Insights
CDKN2B-AS1 is upregulated in laryngeal squamous cell cancer (LSCC) and promotes tumor growth by regulating the miR-497/CDK6 axis. This long noncoding RNA may be a potential therapeutic target for LSCC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Long noncoding RNA CDKN2B-AS1 (antisense RNA 1) is implicated in various cancers.
- Its specific functions and regulatory mechanisms in laryngeal squamous cell cancer (LSCC) are not well understood.
Purpose of the Study:
- To investigate the biological roles of CDKN2B-AS1 in LSCC.
- To elucidate the underlying regulatory mechanisms of CDKN2B-AS1 in LSCC progression.
Main Methods:
- Real-time quantitative PCR (qRT-PCR) to measure expression of CDKN2B-AS1, miR-497, and CDK6 in LSCC tissues and cell lines.
- Functional assays to assess the impact of CDKN2B-AS1 on LSCC cell proliferation, apoptosis, migration, and invasion.
- Bioinformatics analysis and luciferase activity assays to determine the interaction between CDKN2B-AS1 and miR-497.
Main Results:
- CDKN2B-AS1 expression is significantly elevated in LSCC tissues compared to normal tissues.
- High CDKN2B-AS1 levels correlate with lymph node metastasis and advanced clinical stage.
- CDKN2B-AS1 knockdown inhibits LSCC cell proliferation, induces apoptosis, and suppresses migration and invasion.
- CDKN2B-AS1 acts as an oncogenic lncRNA in LSCC by regulating the miR-497/CDK6 axis.
Conclusions:
- CDKN2B-AS1 plays an oncogenic role in LSCC tumorigenesis via the miR-497/CDK6 pathway.
- CDKN2B-AS1 represents a potential therapeutic target for LSCC treatment.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
Inhibition of Cdk Activity
MicroRNAs
MicroRNAs
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...